The global Chemotherapy-induced Nausea and Vomiting Drugs market was valued at US$ 1689.4 million in 2020 and is expected to reach US$ 2358.3 million by the end of 2027, growing at a CAGR of 4.4% during 2021-2027.
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
North America is the largest consumption place, with a consumption market share nearly 51% in 2017; Europe is the second largest consumption place with the consumption market share of 21% in 2017.
Market competition is not intense. Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis etc. are the leaders of the industry with the market share are about 66% in 2017.
Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Chemotherapy-induced Nausea and Vomiting Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche, Mylan, Tesaro and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Type
- 5-HT3 Inhibitors
- NK1 Inhibitors
Segment by Application
- Highly Emetogenic Chemotherapy
- Moderately Emetogenic Chemotherapy
- Low Emetogenic Chemotherapy
Table of Content:
1 Chemotherapy-induced Nausea and Vomiting Drugs Market Overview
2 Chemotherapy-induced Nausea and Vomiting Drugs Market Competition by Manufacturers
3 Chemotherapy-induced Nausea and Vomiting Drugs Retrospective Market Scenario by Region
4 Global Chemotherapy-induced Nausea and Vomiting Drugs Historic Market Analysis by Type
5 Global Chemotherapy-induced Nausea and Vomiting Drugs Historic Market Analysis by Application
6 Key Companies Profiled
7 Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Chemotherapy-induced Nausea and Vomiting Drugs Market Dynamics
10 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta
Peter Barzilai is a high school pitcher and college rower turned longtime World News journalist. Peter has also written for Buzz Feed and Huffington Post and many other major publications, Peter Loves everything about sports and loves to write on trending topics and he is DailyFactsNTrends member since 2017.